EUVIMEDEUVIMED entdecken
Crossref

Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs)

Ilaria Ammendolia, Cristina Mondello, Emanuela Esposito, Gioacchino Calapai, Mariaconcetta Currò, Paola Midiri, Bernardo Firenzuoli, Alberto Noto, Antonino Cancellieri, Luigi Cardia, Alessio Ardizzone, Fabrizio Calapai

Naunyn-Schmiedeberg's Archives of Pharmacology · 22.08.2026

DOI: 10.1007/s00210-026-05813-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 22.08.2026. Verfasst von Ilaria Ammendolia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Simple Departmental Unit of Pharmacy, IRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy. Die Arbeit nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) semaglutide, liraglutide, and dulaglutide are indicated for diabetes. Semaglutide and liraglutide were also approved for therapy of obesity or weight control. Apprehension has been expressed about the possible link between GLP-1 RAs and suicidality. Drug agencies established no causal relationship, but declaring that this risk cannot be underevaluated. We analyzed spontaneous signals of suspected adverse reactions (SARs) to liraglutide, semaglutide, and dulaglutide from EudraVigilance database for the years 2020-2025, to give a contribution in the definition of safety profile of GLP-1 RAs. SARs to semaglutide, liraglutide, and dulaglutide were analyzed, and descriptive and disproportionality analysis for adverse reactions was performed. Eye disorders were more frequently reported with semaglutide than liraglutide (ROR 2.67; 95% CI 1.54-4.63) and dulaglutide (ROR 1.89; 95% CI 1.30-2.75). Suicidal ideation was disproportionately reported with semaglutide (ROR 6.49; 95% CI 1.57-26.81) and liraglutide (ROR 8.61; 95% CI 1.87-39.45) compared with dulaglutide. Data suggest the need of further research and vigilance on the potential occurrence of eye disorders related to GLP-1 RAs semaglutide and liraglutide use and suggest not to underestimate the possibility of a link between these two drugs and suicidality. Caution is suggested when GLP-1 RAs are prescribed for patients characterized by ophthalmic and neuropsychiatric vulnerability.

Schlagwörter

Stichwörter der Autor:innen

Adverse eventsEye disordersGlucagon-like peptide 1 receptor agonistsPharmacovigilancePsychiatric disordersSuicide

Autor:innen und Institutionen

  • Simple Departmental Unit of Pharmacy, IRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy.
  • Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy.
  • Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, Messina, Italy.
  • Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
  • Department of Mental Health, AUSL Toscana Centro, UFSMIA, Valdinievole, Italy.
  • Department of Human Pathology of Adult and Childhood "Gaetano Barresi", University of Messina, Messina, Italy.

Zitieren

APA

Ammendolia, I., Mondello, C., Esposito, E., Calapai, G., Currò, M., Midiri, P., Firenzuoli, B., Noto, A., Cancellieri, A., Cardia, L., Ardizzone, A., & Calapai, F. (2026). Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs). Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05813-9

Vancouver

Ammendolia I, Mondello C, Esposito E, Calapai G, Currò M, Midiri P, et al. Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs). Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05813-9

BibTeX
@article{Ammendolia2026,
  author = {Ammendolia, Ilaria and Mondello, Cristina and Esposito, Emanuela and Calapai, Gioacchino and Currò, Mariaconcetta and Midiri, Paola and Firenzuoli, Bernardo and Noto, Alberto and Cancellieri, Antonino and Cardia, Luigi and Ardizzone, Alessio and Calapai, Fabrizio},
  title = {Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs)},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-026-05813-9}
}
Kostenlos starten →